This article is more than 5 years old. Information may no longer be current.
VIDEO: Crenolanib, venetoclax demonstrate ‘very exciting’ results in AML
Click Here to Manage Email Alerts
The use of crenolanib in patients with acute myeloid leukemia who were either naïve to previous FLT3 inhibitors or were treated with several FLT3 inhibitors appeared effective with minimal side effects or toxicity, according to Aref Al-Kali, MD, of the Mayo Clinic in Rochester, Minn.
The researchers, who presented the study at the ASCO Annual Meeting, did not find any new significant mutations while the patient population was on crenolanib, Al-Kali told HemOnc Today.
“[The] plan in the future is to hopefully expand [the results] more to bigger studies to see if we can get approval for this drug,” he said.
In addition, Al-Kali discusses the results of another study that demonstrated that the combination of low-dose cytarabine with venetoclax (Venclexta; Genentech, AbbVie) improved a patients’ overall response rate to 60% - significantly higher than the standard of 25% to 30% for low-dose cytarabine.
“Now is the planning for future studies, and hopefully, to expand [the treatment] for patients who are in dire need for better therapies,” he said.